Powder: -20°C for 3 years
In solvent: -80°C for 2 years
[Pyr1]-Apelin-13 is a potent and selective endogenous Apelin receptor (APJ) agonist.
Description | [Pyr1]-Apelin-13 is a potent and selective endogenous Apelin receptor (APJ) agonist. |
In vitro | [Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release both in vitro and in vivo[1]. |
In vivo | [Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction[1]. [Pyr1] apelin-13 (1, 5 μg) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5 μg) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5 μg dose also produces significant attenuation in paw withdrawal threshold than SCI animals from the second week post SCI[2]. |
Synonyms | [pGlu1]-Apelin-13 |
Molecular Weight | 1533.8 |
Formula | C69H108N22O16S |
CAS No. | 217082-60-5 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
H2O: 50 mg/mL (32.60 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
[Pyr1]-Apelin-13 217082-60-5 GPCR/G Protein Apelin receptor inhibit [Pyr1]Apelin13 [pGlu1]-Apelin-13 [Pyr1] Apelin 13 Inhibitor [Pyr-1]-Apelin-13 inhibitor